<DOC>
	<DOCNO>NCT01844674</DOCNO>
	<brief_summary>This open-label , multicenter , 3-period , fixed-sequence study evaluate effect multiple oral dos vemurafenib pharmacokinetics single oral dose tizanidine participant BRAFV600 mutation-positive metastatic malignancy . Participants receive single oral dose tizanidine Day 1 , vemurafenib orally twice daily Days 2 21 , tizanidine vemurafenib Day 22 . Eligible participant option continue treatment vemurafenib part extension study ( NCT01739764 ) .</brief_summary>
	<brief_title>A Study Effect Vemurafenib Pharmacokinetics Single Dose Tizanidine Patients With BRAFV600 Mutation-Positive Metastatic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Adults 18 70 year age , inclusive Unresectable Stage IIIc IV metastatic melanoma positive BRAFV600 mutation malignant tumor type harbor V600 activate mutation BRAF , determine Cobas 4800 BRAFV600 Mutation Test DNA sequence method Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy great equal ( &gt; /= ) 12 week Participant consume tobacco nicotinecontaining product 42 day prior first dose study drug , must agree refrain product study Adequate hematologic , renal liver function Prior treatment vemurafenib BRAF inhibitor within 42 day Day 1 History current clinically significant cardiac pulmonary dysfunction , include current uncontrolled Grade &gt; /= 2 hypertension unstable angina Current dyspnea rest due complication advance malignancy requirement supplemental oxygen Active central nervous system lesion ( participant radiographically unstable , symptomatic lesion ) Participants CYP1A2 gene mutation ( 3113G &gt; A ) , either one two allele Allergy hypersensitivity vemurafenib tizanidine formulation Current severe uncontrolled systemic disease Inability unwillingness swallow pill History malabsorption condition would interfere enteral absorption study treatment History clinically significant liver disease ( include cirrhosis ) , current alcohol abuse , human immunodeficiency ( HIV ) infection require antiretroviral treatment , acquire immune deficiency syndrome ( AIDS ) relate illness , active hepatitis B C Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>